Clinical Trial Update: DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer [NA]

View source ↗

Summary

A clinical trial at Ohio State University is evaluating DCE-MRI guided neoadjuvant chemotherapy for borderline-resectable pancreatic cancer and is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: Ohio State University | Conditions: Borderline-resectable Pancreatic Cancer | NA | Status: RECRUITING